Reports Q2 revenue $976,000, consensus $1.23M. Lucid had cash and cash equivalents of $24.9M as of June 30, compared to $18.9M as of December 31, 2023. “I am very pleased with the excellent progress Lucid has made on multiple fronts during the second quarter and recent weeks, specifically the progress made related to EsoGuard’s clinical data,” said Lishan Aklog, Lucid’s Chairman and CEO. “We are now fully armed with a complete body of clinical data and well-positioned for our final push towards broad coverage and reimbursement to drive EsoGuard revenue and revenue growth.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
- Lucid Diagnostics’ EsoGuard esophageal precancer testing shows efficacy
- Lucid Diagnostics announces record quarterly EsoGuard test volume
- Lucid Diagnostics announces data from ESOGUARD BE-1 study of EsoGuard
- Lucid Diagnostics files to sell 72.36M shares of common stock for holders